

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2018

https://marketpublishers.com/r/GE393530D85EN.html

Date: June 2018

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: GE393530D85EN

Abstracts

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2018

SUMMARY

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) pipeline Target constitutes close to 16 molecules. The latest report Galectin 3 - Pipeline Review, H1 2018, outlays comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction



of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 9 and 5 respectively. Report covers products from therapy areas Oncology, Respiratory, Cardiovascular, Gastrointestinal, Dermatology, Genito Urinary System And Sex Hormones, Ophthalmology, Undisclosed, Immunology, Metabolic Disorders and Musculoskeletal Disorders which include indications Pulmonary Fibrosis, Atopic Dermatitis, Breast Cancer, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Prostate Cancer, Unspecified, Atrial Fibrillation, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Diabetic Nephropathy, Fibrosis, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis sicca (Dry Eye), Kidney Fibrosis, Liver Cirrhosis, Metastatic Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Portal Hypertension, Pulmonary Arterial Hypertension, Sarcomas and Skin Cancer.

Furthermore, this report also reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)

The report reviews Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted



therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics and enlists all their major and minor projects

The report assesses Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage



Identify and understand the targeted therapy areas and indications for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Global Markets Direct Report Coverage

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding

Proteinor Mac 2 Antigen or LGALS3) - Overview

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific

Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding

Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific

Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding

Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific

Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding

Proteinor Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics

Development

Galectin Therapeutics Inc

Galecto Biotech AB

GlycoMimetics Inc

iTeos Therapeutics SA

MandalMed Inc

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific

Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding

Proteinor Mac 2 Antigen or LGALS3) - Drug Profiles

Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gal-200 - Drug Profile

Product Description

Mechanism Of Action



R&D Progress

GAL-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gal-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMCT-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Galectin-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protearin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug

Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Galectin-3 for Cardiovascular Disease, Fibrosis and Oncology



- Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Galectin-1, 3, 9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System

Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TFD-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Dormant Products

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Discontinued Products

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Product Development Milestones Featured News & Press Releases

Jun 04, 2018: Galectin Therapeutics Announces Richard E. Uihlein Elected Chairman of the Board

May 21, 2018: Galecto Biotech Strengthens Executive Team with Appointment of Richard Marshall as Chief Medical Officer

May 14, 2018: Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting

Apr 18, 2018: Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018 Apr 16, 2018: Galectin Therapeutics Late-Breaker Presentation at The International



Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis

Apr 04, 2018: Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018

Mar 08, 2018: Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference

Jan 25, 2018: Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs

Dec 14, 2017: Galectin Therapeutics Provides Corporate Update at Annual Meeting

Dec 05, 2017: Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial

Dec 04, 2017: Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017

Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial

Oct 20, 2017: Galectin Therapeutics to Present Clinical Data at The Liver Meeting 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis

Sep 14, 2017: G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals

Sep 12, 2017: Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Galectin Therapeutics Inc, H1 2018

Pipeline by Galecto Biotech AB, H1 2018

Pipeline by GlycoMimetics Inc, H1 2018

Pipeline by iTeos Therapeutics SA, H1 2018

Pipeline by MandalMed Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Galectin Therapeutics Inc Galecto Biotech AB GlycoMimetics Inc iTeos Therapeutics SA MandalMed Inc



I would like to order

Product name: Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific

Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding

Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2018

Product link: https://marketpublishers.com/r/GE393530D85EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE393530D85EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970